Table 2.
Prevalence of patients with appetite loss during lenvatinib treatment for unresectable HCC (n = 63).
| Appetite loss | |
| Any grade | 43 (68%) |
| Grade 1 | 29 (46%) |
| Grade 2 | 13 (21%) |
| Grade 3 | 1 (2%) |
HCC: Hepatocellular carcinoma.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.